Skip to main content
TipRanks
Go Ultimate75% OFF

Thomas Franke Insider Profile

4 Followers

Thomas Franke, Director at Omega Healthcare, holds 113.49K shares in Omega Healthcare (Ticker: OHI). Most recently, Thomas Franke Bought 6,000 shares of Omega Healthcare on May 25, 2016 for an estimated value of $186.04K.

Thomas Franke's Trading History

OHI
Omega Healthcare
May 25, 2016DirectorInformative Buy186.04K$5.34M
OHI
Insider Shares: 113.49K (0.06%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
May 25, 2016Informative Buy$186.04K6,000$31.00+10.30%
May 17, 2016Uninformative Buy$12.51K382$32.76―
Feb 18, 2016Uninformative Buy$12.51K444$28.18―
Feb 16, 2016Informative Buy$457.86K16,000$28.61+17.90%
Nov 19, 2015Uninformative Buy$12.49K382$32.69―

You May Also Like

Thomas Franke insider profile FAQ

What is the percentage of profitable transactions made by Thomas Franke?
The percentage of profitable transactions made by Thomas Franke is 100%.
What is the average return per transaction made by Thomas Franke?
The average return per transaction made by Thomas Franke is 14.10%.
What stocks does Thomas Franke hold?
Thomas Franke holds: OHI stocks.
What was Thomas Franke’s latest transaction?
Thomas Franke’s latest transaction was an Informative Buy of $186.04K.
What was Thomas Franke's most profitable transaction?
Thomas Franke’s most profitable transaction was an Informative Buy of OHI stock on February 16, 2016. The return on the trade was 17.90%.
What is Thomas Franke's role in Omega Healthcare?
Thomas Franke's role in Omega Healthcare is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.